History, Founder and Co-Founding Team Members

Our Story

The Kerecis story began in 2007, when the company founder Fertram Sigurjonsson began entrepreneurial projects in the medical devices field. During his career in several medical device companies, Fertram had built a deep understanding of the industry’s value chain and developed interest in diabetic wounds and human-tissue trauma.

Gudmundur Fertram

Building on his experience, ranging from software solutions at his startup in Denmark, to the development and commercialization of medical devices for human tissue repair as an employee within two medical device companies, coupled with his youth experience in the fishing village of Isafjordur, Fertram came up with the concept of using fish skin to heal damaged tissue.

Fertram’s bachelor’s degree was in chemistry from the University of Iceland. His master’s of Engineering degree, was from the Technical University of Denmark.

Over the initial years of Kerecis, Fertram sought support from former colleagues he had worked with during his career. The colleagues included medical doctors Baldur Tumi Baldursson and Hilmar Kjartansson, U.S. patent attorney Ernest Kenney and lawyer Baldvin Bjorn Haraldsson. Fertram’s father, Sigurjon N. Olafsson, Associate Professor of Chemistry at the University of Iceland and Fertram’s wife Fanney, a biotech engineer with background in pharmaceutical regulatory affairs, were also involved.

In August 2023 Kerecis became Iceland’s first Unicorn when it sold to the Danish company Coloplast for $1.3 Billion.

Kerecis Co-Founding Team Members

Baldur Baldursson
Baldur T. Baldursson
MD, PhD
Hilmar Kjartansson
Hilmar Kjartansson
MD
Baldvin B. Haraldsson
J. Ernest Kenney
Dr. Sigurjon N. Olafsson
Fanney Kr. Hermannsdottir

Milestones

Fertram returns to Iceland and begins entrepreneurial projects in the medical devices field.
2007
Intact Fish Skin for Tissue Regeneration - Kerecis logo
The name of FnF was changed to Kerecis
2009
2009
2009
January
Proof-of-concept grant received from Iceland’s Technology Development Fund. First prototypes created with the help of Matis Laboratories.
2009
June
Full grant received from Iceland’s Technology Development Fund.
2009
September
Laboratory established in Ísafjörður, Iceland, and first employee, chemical engineer Dóra Hlín, hired. Technology development program accelerated.
2009
Investment Round
January
Seed investment round closed with the government-owned New Business Venture Fund.
2010
New Shareholders
Baldursson, Kjartansson, Kenney, Ólafssonand Haraldsson became shareholders.
2010
Reykjavik
February
Office opened in Reykjavik, Iceland, and employees hired.
2010
Series A
Early 2011 Series A investment round closed with milestone payments related to the advancement of the technology development program.
2011
Rejected
Disaster struck when the FDA rejected Kerecis' initial regulatory application and asked for more clinical data. Milestone payment was delayed from the investor and office moved to Fertram's living room.
2011
Scientific Advisory Board
August
Kerecis appoints a Scientific Advisory Board with world-leading scientists.
2013
Clearance
Clinical trials completed, new submission made to the FDA, and clearance received.
2014
Investment Rounds
An investment round was completed, and Fertram left consulting projects to focus exclusively on running Kerecis.
2014
nff-helsinki
Fertram participated in the Northern Future Forum and met with heads of government to discuss entrepreneurship and education.
2014
Kerecis received a grant from the U.S. Department of Defense to adapt products for burn and blast injuries.
2015
Washington DC
Kerecis stepped up operations in the U.S. and transferred its Sales & Marketing head office to the Washington, D.C., area.
2015
$1.000.000
First year of U.S. sales completed with $1 million in revenue.
2015
Icelandic innovation award logo
October
On October 30, 2018, Kerecis received the Icelandic Innovation Award.
2018
Double-Blind study
A second randomized, double-blind study on Kerecis technology was completed and published.
2019
Growth accelerated in the U.S., and Steve DiBiasio joined the company to lead sales growth.
2019
Switzerland
Operations of the Switzerland-based company Phytoceuticals AG (now Kerecis AG) were acquired, giving Kerecis control of its plant-based fatty-acid tissue technology.
2019
$21M
Kerecis closed a Series C round with $21 million in total funding. Laurene Powell Jobs was among the investors.
2020
Mike Cadigan helped close the round as a financial advisor and later joined the company as CFO.
2020
Controlled Study
A third randomized controlled study was completed and published.
2021
Guðmundur Óskarsson joined the company to lead product management and marketing.
2021
Fertram named an EY Entrepreneur Of The Year.
2021
300
Number of staff exceeded 300.
2022
$100M
July Kerecis completed a Series D round with $100 million in total funding.
2022
LEGO brand owner KIRKBI led the investment round. The company stated that no further investment rounds were needed to fund day-to-day operations.
2022
$85M
Kerecis ended the year with $85 million in revenue and profitable operations.
2022
Dan Mooradian joined Kerecis to lead research & development.
2023
Minneapolis
Laboratory and distribution centers were established in Minneapolis, MN.
2023
Coloplast logo
Kerecis was acquired by Coloplast A/S for USD 1.3 billion.
2023
© 2010 – 2025 Kerecis. All Rights Reserved